NPPA fixes prices of 22 drug formulations

The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 22 formulations used for treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.

While National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator’s website said.

The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.

The regulator has fixed ceiling prices of Co-trimoxazole (Sulphamethoxazole(A) and Trimethoprim(B) tablets used for treating a variety of bacterial infections and oral rehydration salt (ORS).

It has also fixed the retail prices of drugs manufactured and marketed by various firms such as Omeprazole Domperidone capsule used for treatment of acidity and gastroesophageal reflux disease, Clotrimazole Beclomethasone cream used for treating variety of inflamed fungal skin infections.

The regulator has also fixed the retail price of Rosuvastatin Clopidogrel tablet used to lower cholesterol level and triglycerides and Tenofovir Disoproxil Fumarate Lamividine Efavirenz tablet used in treatment of HIV, among others.

The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.

It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

  • Related Posts

    NHS backs delayed‑release treatment for cystinosis

    Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Mumbai/Pune: In a major regulatory enforcement action aimed at safeguarding public health, the Maharashtra Food and Drug Administration (FDA) has permanently cancelled the Ayurvedic drug manufacturing licence of Pune-based M/s Inducare Pharma…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    NHS backs delayed‑release treatment for cystinosis

    NHS backs delayed‑release treatment for cystinosis

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care

    AmeriHealth Home Healthcare Celebrates 5 Years of Compassionate Care